Literature DB >> 15102346

Brain metastases.

Antonio Marcilio Padula Omuro1, Lauren Eileen Abrey.   

Abstract

Despite advances in the treatment of cancer, brain metastases appear to be increasing in frequency and are associated with a poor prognosis. Type of tumor, age, performance status, and extent of systemic disease are important prognostic factors that should be taken into consideration when making treatment decisions. Patients with a good performance status and controlled systemic disease may benefit from aggressive focal therapies (surgery or radiosurgery). Whole brain radiotherapy seems to increase local control but is associated with the risk of delayed cognitive deterioration in long-term survivors. In spite of this, whole brain radiotherapy remains the standard of care for those patients with poorer prognosis and for the treatment of recurrence after focal therapy. Chemotherapy has a limited role in the treatment of brain metastases but should be considered in selected patient populations.

Entities:  

Mesh:

Year:  2004        PMID: 15102346     DOI: 10.1007/s11910-004-0040-6

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  19 in total

1.  A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.

Authors:  L E Abrey; J D Olson; J J Raizer; M Mack; A Rodavitch; D Y Boutros; M G Malkin
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

2.  Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases.

Authors:  C Christodoulou; D Bafaloukos; P Kosmidis; E Samantas; A Bamias; P Papakostas; A Karabelis; C Bacoyiannis; D V Skarlos
Journal:  Ann Oncol       Date:  2001-02       Impact factor: 32.976

3.  Intracranial metastases from systemic cancer.

Authors:  J B Posner; N L Chernik
Journal:  Adv Neurol       Date:  1978

4.  Therapy of venous thromboembolism in patients with brain metastases.

Authors:  D Schiff; L M DeAngelis
Journal:  Cancer       Date:  1994-01-15       Impact factor: 6.860

5.  Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.

Authors:  Leo J Schouten; Joost Rutten; Hans A M Huveneers; Albert Twijnstra
Journal:  Cancer       Date:  2002-05-15       Impact factor: 6.860

6.  Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases.

Authors:  D Antonadou; M Paraskevaidis; G Sarris; N Coliarakis; I Economou; P Karageorgis; N Throuvalas
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

7.  Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital.

Authors:  K A Sepkowitz; A E Brown; E E Telzak; S Gottlieb; D Armstrong
Journal:  JAMA       Date:  1992-02-12       Impact factor: 56.272

Review 8.  Molecular mechanisms of tumor invasion and metastasis: an integrated view.

Authors:  R A Cairns; R Khokha; R P Hill
Journal:  Curr Mol Med       Date:  2003-11       Impact factor: 2.222

9.  The role of tumor size in the radiosurgical management of patients with ambiguous brain metastases.

Authors:  Eric L Chang; Samuel J Hassenbusch; Almon S Shiu; Frederick F Lang; Pamela K Allen; Raymond Sawaya; Moshe H Maor
Journal:  Neurosurgery       Date:  2003-08       Impact factor: 4.654

10.  A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases.

Authors:  Penny K Sneed; John H Suh; Steven J Goetsch; Seema N Sanghavi; Richard Chappell; John M Buatti; William F Regine; Eduardo Weltman; Vernon J King; John C Breneman; Paul W Sperduto; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-01       Impact factor: 7.038

View more
  3 in total

Review 1.  Metastatic disease of the brain: extra-axial metastases (skull, dura, leptomeningeal) and tumour spread.

Authors:  Roberto Maroldi; Claudia Ambrosi; Davide Farina
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

2.  Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.

Authors:  A M Omuro; J J Raizer; A Demopoulos; M G Malkin; L E Abrey
Journal:  J Neurooncol       Date:  2006-04-14       Impact factor: 4.130

3.  A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases.

Authors:  Fabio M Iwamoto; Antonio M Omuro; Jeffrey J Raizer; Craig P Nolan; Adília Hormigo; Andrew B Lassman; Igor T Gavrilovic; Lauren E Abrey
Journal:  J Neurooncol       Date:  2007-11-07       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.